idiopathic

Type: Keyphrase
Name: idiopathic
First reported 55 mins ago - Updated 55 mins ago - 1 reports

Omalizumab Effective for Chronic Hives up to 24 Weeks

Omalizumab ( Xolair , Genentech Inc and Novartis Pharmaceuticals Corporation) is effective at controlling chronic hives for up to 24 weeks, according to results of a clinical trial by Sarbjit S. Saini, MD, from the Johns Hopkins Asthma and Allergy Center, ... [Published American Journal of Public Health - 55 mins ago]
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Elobixibat and Its Role in Chronic Idiopathic Constipation

Alemi, F., Poole, D., Chiu, J., Schoonjans, K., Cattaruzza, F., Grider, J. et al . (2013) The receptor TGR5 mediates the prokinetic actions of intestinal bile acids and is required for normal defecation in mice. Gastroenterology 144: 145–154.Andresen, ... [Published General Medicine eJournal - 6 hours ago]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Epilepsy

Overview Epilepsy Causes Epilepsy Symptoms Medications Follow-up Prevention Outlook Web Links Epilepsy is a condition in which a person has recurrent seizures. A seizure is defined as an abnormal, disorderly discharging of the brain's nerve cells, resulting ... [Published eMedicine Health - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Disabled woman criticises “unprofessional” Stevenage train staff

Martin DunneThursday, July 24, 20147:12 AMA disabled woman has criticised a train operator for its “ridiculously unprofessional” support service.To send a link to this page to a friend, you must be logged in.Carole Pont pre-booked First Capital Connect ... [Published Herts 24 - Jul 24 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 3 reports

Some good news out of the U.K. for Peter Greenleaf's Sucampo

A key U.K. health agency has given the nod to Sucampo Pharmaceuticals Inc.'s bowel drug Amitiza, opening up public funding for adult patients suffering from chronic idiopathic constipation to receive the treatment.The National Institute for Health and ... [Published Washington Business Journal - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

5 myths about the sudden urge to 'go'

Even though urinary incontinence affects about 25 million Americans and there are many treatment options to improve symptoms, talking about the often unexpected and always urgent need "to go" is still taboo, even with your doctor.In my own practice, I ... [Published WDSU New Orleans - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 2 reports

Sucampo announces publication of NICE recommendation for AMITIZA® (Lubiprostone)

Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ: SCMP), a global biopharmaceutical company, today announced that the United Kingdom’s National Institute of Health and Care Excellence (NICE) has published the technology appraisal guidance recommending ... [Published European Pharmaceutical Review - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Asthma drug relieves chronic hives

The asthma drug omalizumab may provide symptom relief to patients with chronic idiopathic urticaria, results of a recently published study suggest.In the 40-week double-blind study, Sarbjit S. Saini, M.D., of Johns Hopkins Asthma and Allergy Center, Baltimore, ... [Published Dermatology Times - Jul 23 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Fundraiser for 12 y.o. with rare lung disease

GIBRALTER, Mich. (WXYZ) - 12-year-old Anna Gould fights back tears as she talks about the most trying months of her young life.Since being diagnosed with a rare lung disease back in March, the child from Gibraltar has been through an unthinkable ordeal, ... [Published WXYZ - Jul 23 2014]
First reported Jul 21 2014 - Updated Jul 22 2014 - 2 reports

Mazor Posts Data Results from IMAST Meeting

Mazor Robotics posted results of data being presented July 16-19 at the 21st International Meeting on Advanced Spine Techniques (IMAST) meeting in Valencia, Spain. According to a release from the company, an e-poster titled, Retrospective, Five-Center ... [Published Individual.com - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Developing a provisional, international Minimal Dataset for Juvenile Dermatomyositis: for use in ...

Juvenile dermatomyositis (JDM) is a rare but severe autoimmune inflammatory myositis of childhood. International collaboration is essential in order to undertake clinical trials, understand the disease and improve long-term outcome.The aim of this study ... [Published 7thSpace - Jul 21 2014]
Entities: Myositis, Myopathy, Cohort
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Week One Done. Week Two Here I Come.

Wow. That was a trying week. I for sure learned not to eat all my weekly points at one time haha. It was NOT worth it by the end of the week. I BARELY made it. In my accomplishments for last week I lost 5.5 lbs. I wish every week was going to be like ... [Published Weight Watchers - Jul 21 2014]

Quotes

"I'm very enthusiastic about having a new therapy available for something that we've had difficulty with for many years, something that has so much of an impact on the population" said Myron Zitt, MD, from the State University of New York at Stony Brook, who was not involved in the trials
...make AMITIZA more widely accessible to patients in the U K who may benefit from it," stated Peter Greenleaf, Chief Executive Officer of Sucampo. "Through more than eight years of experience and eight million prescriptions dispensed globally, AMITIZA has been demonstrated to be an effective treatment option with a well-tolerated safety profile. Today's NICE recommendation for AMITIZA is an important step in allowing us to fulfill Sucampo's mission of meeting unmet patient needs in the U K , and on a global basis."
"Through more than eight years of experience and eight million prescriptions dispensed globally, Amitiza has been demonstrated to be an effective treatment option with a well-tolerated safety profile."
Commenting on the Group's half year results, Roche CEO Severin Schwan said: "We had a good first half, driven mainly by our cancer medicines, especially the new breast cancer medicines, Perjeta and Kadcyla, as well as by Diagnostics. We made significant progress in our product pipeline, as the FDA granted Breakthrough Therapy Designation for our cancer immunotherapy candidate anti-PDL1, as well as priority reviews for Avastin in two new indications and fast track designation for a promising new antibiotic. In Diagnostics, we also gained an important FDA approval for use of our HPV test in primary screening for cervical cancer. Based on our half year performance, I am confident that we will meet our full-year targets."

More Content

All (310) | News (237) | Reports (0) | Blogs (68) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Omalizumab Effective for Chronic Hives up to 24... [Published American Journal of Public Health - 55 mins ago]
Rigid Thoracoscopy or Flexi-Rigid Pleuroscopy? [Published General Medicine eJournal - 6 hours ago]
Elobixibat and Its Role in Chronic Idiopathic C... [Published General Medicine eJournal - 6 hours ago]
Rare Primary Headaches [Published General Medicine eJournal - 6 hours ago]
Alcohol Consumption and Systolic Ventricular Fu... [Published General Medicine eJournal - 8 hours ago]
What your feet say about your health [Published Mother Nature Network - Jul 25 2014]
Roche's 1H14 Earnings & Revenues Up Y/Y, Outloo... [Published Yahoo! Finance - Jul 25 2014]
'Subconscious' driving defence used in fatal cr... [Published Bayside Bulletin / Redland Times - Jul 25 2014]
Evaluation of an apparatus to be combined with ... [Published 7thSpace - Jul 25 2014]
Sucampo Pharmaceuticals Has Returned 13.9% Sinc... [Published Comtex SmarTrend - Jul 24 2014]
Sucampo announces publication of NICE recommend... [Published Medical News Today - Jul 24 2014]
NICE recommends Sucampo’s Amitiza for chronic i... [Published Pharmaceutical Technology - Jul 24 2014]
Monitoring Disease Activity and Progression in ... [Published Sexual Development - Jul 24 2014]
Treatment of Alveolar-Pleural fistula with endo... [Published CHEST - Jul 24 2014]
Epilepsy [Published eMedicine Health - Jul 24 2014]
Roche Bearer Share : with good half year perfor... [Published 4 Traders - Jul 24 2014]
Disabled woman criticises “unprofessional” Stev... [Published Herts 24 - Jul 24 2014]
Studies by I.B. Gubrij and Co-Authors Describe ... [Published HispanicBusiness.com - Jul 24 2014]
FDA Confirms Approval of Gilead's Zydelig; FDA ... [Published BioMedReports - Jul 24 2014]
Current understanding of feline epilepsy, diagn... [Published Thomson Veterinary Healthcare Communications - Jul 24 2014]
Some good news out of the U.K. for Peter Greenl... [Published Washington Business Journal - Jul 23 2014]
Lilly’s Efient and Sucampo's Amitiza win NICE b... [Published PMLive - Jul 23 2014]
NICE recommends Amitiza to treat long-term, pai... [Published Pharma Letter - Jul 23 2014]
5 myths about the sudden urge to 'go' [Published WDSU New Orleans - Jul 23 2014]
Sucampo announces publication of NICE recommend... [Published European Pharmaceutical Review - Jul 23 2014]
Cost watchdog expands NHS use of bloodthinner E... [Published Pharma Times - Jul 23 2014]
Asthma drug relieves chronic hives [Published Dermatology Times - Jul 23 2014]
Sucampo Announces Publication of NICE Recommend... [Published FirstWord Pharma - Jul 23 2014]
Macitentan, A New Tool in Pulmonary Arterial Hy... [Published General Medicine eJournal - Jul 23 2014]
MCS Patients in Puerto Rico Find Environmental ... [Published Prlog - Jul 23 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Data Presented at IMAST Shows Over 99 Percent A... [Published Business Wire Technology News - Jul 17 2014]
ORLANDO, Fla.--(BUSINESS WIRE)--Mazor Robotics, Ltd. (TASE: MZOR; NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced results of data being presented July 16-19 at the 21st International Meeting on Advanced ...
Data Presented at IMAST Shows Over 99 Percent A... [Published Business Wire Health News - Jul 17 2014]
ORLANDO, Fla.--(BUSINESS WIRE)--Mazor Robotics, Ltd. (TASE: MZOR; NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced results of data being presented July 16-19 at the 21st International Meeting on Advanced ...
Hoisted By Her Own Petard: A Qualified Epidemio... [Published Drug and Device Law - Jul 15 2014]
            Birth defects are scary.  We suspect most parents among our readers can remember their relief upon hearing the pronouncement “normal” during a sonogram and when the post-birth count of fingers and toes came up as expected.  When there is a ...
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Science: Science News - Jul 14 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation ...
Synergy Pharmaceuticals Reaches Halfway Mark fo... [Published Business Wire Health News - Jul 14 2014]
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Reaches Halfway Mark for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
3D Systems Unveils 3D printed Bespoke™ Braces f... [Published 3D Systems Latest News - Jun 09 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.